论文部分内容阅读
对于浸润性膀胱癌患者,保留膀胱的治疗策略包括经尿道膀胱肿瘤电切术(TURBT)及术后系统的放化疗。为了比较紫杉醇与氟尿嘧啶这两种化疗药物用于TURBT术后治疗的效果、安全性及耐受性,作者进行了一项随机多中心2期临床试验。试验选取美国24所医疗中心2002年至2008年共93例T2~T4a期膀胱癌患者,患者施行TURBT后,随机分为两组(紫杉醇组46例、氟尿嘧啶组47例),术后8周内开始诱导治疗,治疗方案分别为连续13天、2次/d的放疗联合紫
For patients with invasive bladder cancer, treatment strategies that preserve the bladder include transurethral resection of the bladder tumor (TURBT) and postoperative chemoradiation. To compare the efficacy, safety, and tolerability of two chemotherapeutic agents, paclitaxel and fluorouracil, for post-TURBT treatment, the authors conducted a randomized multicenter phase 2 trial. A total of 93 T2-T4a bladder cancer patients from 24 medical centers in the United States from 2002 to 2008 were selected and randomly divided into two groups (46 in the paclitaxel group and 47 in the fluorouracil group). After TURBT, Start induction therapy, treatment options were continuous for 13 days, 2 times / d radiotherapy combined with purple